SEC Comment Letter for IMMUNIC, INC. (IMUX) (CIK 0001280776) (IMUX) — Nov 30, 2023
IMMUNIC, INC. (IMUX) (CIK 0001280776)
Date: Nov. 30, 2023 · CIK: 0001280776 · Accession: 0000000000-23-013078
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275717
Letter
United States securities and exchange commission logo November 30, 2023 Daniel Vitt Chief Executive Officer Immunic, Inc. 1200 Avenue of the Americas Suite 200 New York, NY 10036 Re:Immunic, Inc. Registration Statement on Form S-3 Filed November 22, 2023 File No. 333-275717 Dear Daniel Vitt: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ilan Katz
Show Raw Text
United States securities and exchange commission logo
November 30, 2023
Daniel Vitt
Chief Executive Officer
Immunic, Inc.
1200 Avenue of the Americas
Suite 200
New York, NY 10036
Re:Immunic, Inc.
Registration Statement on Form S-3
Filed November 22, 2023
File No. 333-275717
Dear Daniel Vitt:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Ilan Katz